Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
Results
All zinc studies
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchZincZinc (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Ventilation -5% Improvement Relative Risk Discharge 6% Recovery, dyspnea, cough.. 10% Recovery, dyspnea 50% Recovery, fever 32% Recovery, cough 12% Recovery, D+Z, dyspnea, c.. 16% Recovery, D+Z, dyspnea 77% Recovery, D+Z, fever 17% Recovery, D+Z, cough 18% Zinc  Partap et al.  EARLY TREATMENT  DB RCT Is early treatment with zinc beneficial for COVID-19? Double-blind RCT 85 patients in India (April 2021 - August 2022) No significant difference in outcomes seen c19early.org Partap et al., Current Developments in.., Jul 2023 Favors zinc Favors control

Vitamin D and zinc supplementation to improve treatment outcomes among COVID-19 patients in India: results from a double-blind randomized placebo-controlled trial

Partap et al., Current Developments in Nutrition, doi:10.1016/j.cdnut.2023.101971, NCT04641195
Jul 2023  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Early terminated factorial RCT with 46 vitamin D, 48 zinc, 44 vitamin D + zinc, and 43 placebo patients in India.
The most serious outcome (ventilation) numbers do not seem realistic. Authors do not specify outcomes per group, but with one event for non-zinc, we know that either the vitamin D only or the placebo group had zero events, which does not match the reported RRs. All 7 RRs are close to 1.0: for D vs. non-D, Z vs. non-Z, D+Z vs. placebo, D vs. placebo, Z vs. placebo, D<20ng/mL vs. non-D, and D>20ng/mL vs. non-D. This suggests unreliable data or analysis (e.g., inappropriate use of Poisson regression). We will update when authors respond.
The trial is also unusual in that the primary analyses are unadjusted and compare one treatment with a combination of another treatment and placebo.
There are very large baseline differences, e.g., 35 vs. 15% 60+ for zinc vs. non-zinc. There was only 181 patients recruited from 700 planned.
There is limited room for improvement with the population studied that recovered very quickly within a median of 3 days. Oral cholecalciferol takes 3-7 days for complete conversion into the biologically active 1,25-dihydroxyvitamin D. Authors could have provided treatment with much faster onset of action, e.g., using calcitriol.
There was very little improvement in D/zinc levels with the administration used and the baseline deficiency levels. Only 4% of people went from zinc deficient to sufficient, and only 8% went from vitamin D <30ng/mL to >30ng/mL, and most or all of these improvements may have been after patients already recovered.
Notwithstanding the limitations above, we note that, while small, the effect for most outcomes is positive for vitamin D and zinc, and in most cases, the effect in the combined vitamin D + zinc group is larger.
Data for this study is not available.
This study includes zinc and vitamin D.
risk of mechanical ventilation, 5.0% higher, RR 1.05, p = 0.82, treatment 43, control 42, zinc vs. placebo.
risk of no hospital discharge, 6.0% lower, HR 0.94, p = 0.80, treatment 43, control 42, zinc vs. placebo.
risk of no recovery, 10.0% lower, HR 0.90, p = 0.67, treatment 41, control 42, zinc vs. placebo, dyspnea, cough, or fever, Table S8.
risk of no recovery, 50.0% lower, HR 0.50, p = 0.35, treatment 43, control 42, zinc vs. placebo, dyspnea, Table S8.
risk of no recovery, 32.0% lower, HR 0.68, p = 0.26, treatment 43, control 42, zinc vs. placebo, fever, Table S8.
risk of no recovery, 12.0% lower, HR 0.88, p = 0.63, treatment 43, control 42, zinc vs. placebo, cough, Table S8.
risk of no recovery, 16.0% lower, HR 0.84, p = 0.51, treatment 39, control 42, zinc + vitamin D vs. placebo, dyspnea, cough, or fever, Table S8.
risk of no recovery, 77.0% lower, HR 0.23, p = 0.06, treatment 39, control 42, zinc + vitamin D vs. placebo, dyspnea, Table S8.
risk of no recovery, 17.0% lower, HR 0.83, p = 0.57, treatment 39, control 42, zinc + vitamin D vs. placebo, fever, Table S8.
risk of no recovery, 18.0% lower, HR 0.82, p = 0.50, treatment 39, control 42, zinc + vitamin D vs. placebo, cough, Table S8.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Partap et al., 11 Jul 2023, Double Blind Randomized Controlled Trial, placebo-controlled, India, peer-reviewed, 13 authors, study period 22 April, 2021 - 1 August, 2022, trial NCT04641195 (history).
Contact: upartap@hsph.harvard.edu, mina@hsph.harvard.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperZincAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit